Hydroxychloroquine and Chloroquine Prescribing Patterns by Provider Specialty Following Initial Reports of Potential Benefit for COVID-19 Treatment — United States, January–June 2020
- 4 September 2020
- journal article
- research article
- Published by Centers for Disease Control MMWR Office in Morbidity and Mortality Weekly Report (MMWR)
- Vol. 69 (35), 1210-1215
- https://doi.org/10.15585/mmwr.mm6935a4
Abstract
This report describes prescribing patterns for hydroxychloroquine and chloroquine based on provider specialty following initial reports of treatment benefits for COVID-19.Keywords
This publication has 9 references indexed in Scilit:
- Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19The New England Journal of Medicine, 2020
- US Hydroxychloroquine, Chloroquine, and Azithromycin Outpatient Prescription Trends, October 2019 Through March 2020JAMA Internal Medicine, 2020
- Coronavirus Disease 2019–COVID-19Clinical Microbiology Reviews, 2020
- Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19International Journal of Infectious Diseases, 2020
- Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York StateJAMA, 2020
- Recommendations for the measurement of the QT interval during the use of drugs for COVID-19 infection treatment. Updatable in accordance with the availability of new evidenceJournal of Interventional Cardiac Electrophysiology, 2020
- Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trialInternational Journal of Antimicrobial Agents, 2020
- Epidemiology and Estimated Population Burden of Selected Autoimmune Diseases in the United StatesClinical Immunology and Immunopathology, 1997
- Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseasesLupus, 1996